Brief: Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
11/11/2024 21:44
Nov 11 (Reuters) - Quince Therapeutics Inc QNCX.O :
* QUINCE THERAPEUTICS PRESENTS SAFETY DATA FROM PRIOR PHASE
3
ATTEST CLINICAL TRIAL AT 53RD CHILD NEUROLOGY SOCIETY ANNUAL
MEETING
Source text: ID:nBw3ZcVpa
Further company coverage: QNCX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IRulya Therapeutics
See all newsBrief: Quince Therapeutics - Changes Name To Irulya Therapeutics
Brief: Quince Therapeutics - Appoints Brigette Roberts As CEO Effective October 8, 2026
Quince Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update
Quince Therapeutics Q2 net loss widens on acquisition charges